Lupin Manufacturing Solutions appoints Eduardo Jule as Chief Commercial Officer

Veteran pharma and biotech executive brings over 20 years of commercial leadership experience to support LMS's global CDMO and API growth strategy

Lupin Manufacturing Solutions announces expansion of Dabhasa facility

These upgrades will enable advanced development and flexible manufacturing, supporting complex therapeutics and meeting global demand for advanced pharmaceutical solutions

Lupin Manufacturing Solutions partners with PolyPeptide to scale global peptide supply chain

This partnership strengthens LMS as a leading CDMO supplier of peptide materials for both innovator and generic markets

Lupin Manufacturing Solutions unveils dedicated oncology block at Vizag

Lupin enters into BTA with Lupin Manufacturing Solutions

Lupin enters into BTA with Lupin Manufacturing Solutions

Lupin receives FDA’s tentative approval for Sugammadex injection

Sugammadex injection is bioequivalent to Merck’s Bridion injection for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged 2 years and older undergoing surgery

Lupin launches Dasatinib tablets in US, eyes $930 million oncology market

Lupin achieves GMP certification from TGA Australia for Dabhasa API facility

Lupin receives EIR from USFDA for Pithampur Unit-1 Facility with VAI Classification

The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection of the facility from September 16 to September 27, 2024

Lupin receives EIR from USFDA for its Dabhasa facility

The facility is a part of Lupin Manufacturing Solutions